NASDAQ:TPST

Tempest Therapeutics Stock News

etoro logo Buy TPST
*Your capital is at risk
$1.27
-0.0400 (-3.05%)
At Close: Jun 03, 2026
BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeut
BRISBANE, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and
BRISBANE, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and
BRISBANE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and

Penny Stocks To Buy? 5 To Watch Right Now

11:16am, Wednesday, 22'nd Nov 2023
Penny stocks refer to shares of small or micro-cap companies that trade for less than $5 per share. What cheap stocks lack in size and stability, they can potentially make up for in rapid price change
BRISBANE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and
BRISBANE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and

The Secrets Behind a 4000% Biotech Stock Surge

08:06am, Tuesday, 17'th Oct 2023
Remarkably, the stock did not have fundamentally changing news. It did not rocket higher on breaking news that would typically be associated with the whopping gains it experienced.
Tempest Therapeutics TPST, +85.16%, whose stock has gained 2710% over the last five days, saw its stock rise by 8% in premarket trade.
Shares of Tempest Therapeutics Inc. TPST, -8.54% fell more than 8% Friday to conclude a dramatic week in which the stock clocked a one-day gain of nearly 4,000%.
Shares of microcap oncology company Tempest Therapeutics Inc. TPST, -55.06% dropped more than 50% Thursday as investors took a breath after the stock's roughly 40-fold gain on Wednesday.
Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study evaluating TPST-1120 in combination with standard-of-care therapies to treat liver cancer.
Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's
Today, most of Wall Street is watching Tempest Therapeutics (NASDAQ: TPST ). This little-known clinical-stage oncology company has gone from trading at 30 cents per share 24 hours ago to its current s
Tempest Therapeutics (NASDAQ: TPST ) is the stock to watch for today, as its shares are up by a staggering 1,500%. This morning, the cancer therapies company reported positive results for its TPST-112
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE